JP2017101068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017101068A5 JP2017101068A5 JP2017037131A JP2017037131A JP2017101068A5 JP 2017101068 A5 JP2017101068 A5 JP 2017101068A5 JP 2017037131 A JP2017037131 A JP 2017037131A JP 2017037131 A JP2017037131 A JP 2017037131A JP 2017101068 A5 JP2017101068 A5 JP 2017101068A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- alk1
- fusion protein
- preparation according
- angiogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 17
- 108020001507 fusion proteins Proteins 0.000 claims 9
- 102000037865 fusion proteins Human genes 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 4
- 230000033115 angiogenesis Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims 1
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5016808P | 2008-05-02 | 2008-05-02 | |
| US61/050,168 | 2008-05-02 | ||
| US14413109P | 2009-01-12 | 2009-01-12 | |
| US61/144,131 | 2009-01-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014237666A Division JP6194302B2 (ja) | 2008-05-02 | 2014-11-25 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019171838A Division JP2019210298A (ja) | 2008-05-02 | 2019-09-20 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017101068A JP2017101068A (ja) | 2017-06-08 |
| JP2017101068A5 true JP2017101068A5 (enExample) | 2018-02-22 |
Family
ID=41055305
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507463A Expired - Fee Related JP5719766B2 (ja) | 2008-05-02 | 2009-05-01 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2014237666A Expired - Fee Related JP6194302B2 (ja) | 2008-05-02 | 2014-11-25 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2017037131A Withdrawn JP2017101068A (ja) | 2008-05-02 | 2017-02-28 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2019171838A Withdrawn JP2019210298A (ja) | 2008-05-02 | 2019-09-20 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2021144016A Pending JP2021183652A (ja) | 2008-05-02 | 2021-09-03 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011507463A Expired - Fee Related JP5719766B2 (ja) | 2008-05-02 | 2009-05-01 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2014237666A Expired - Fee Related JP6194302B2 (ja) | 2008-05-02 | 2014-11-25 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019171838A Withdrawn JP2019210298A (ja) | 2008-05-02 | 2019-09-20 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
| JP2021144016A Pending JP2021183652A (ja) | 2008-05-02 | 2021-09-03 | 血管新生および周皮細胞組成物を調節するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US8158584B2 (enExample) |
| EP (2) | EP3398966A1 (enExample) |
| JP (5) | JP5719766B2 (enExample) |
| KR (8) | KR20170012595A (enExample) |
| CN (2) | CN102099374B (enExample) |
| AU (5) | AU2009241755B2 (enExample) |
| BR (1) | BRPI0911853A8 (enExample) |
| CA (1) | CA2723449C (enExample) |
| MX (2) | MX391905B (enExample) |
| TW (3) | TWI586364B (enExample) |
| WO (1) | WO2009134428A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057461A2 (en) | 2006-11-02 | 2008-05-15 | Acceleron Pharma, Inc. | Alk1 receptor and ligand antagonists and uses thereof |
| US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
| US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| KR20100090683A (ko) | 2007-11-09 | 2010-08-16 | 제넨테크, 인크. | 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법 |
| TWI586364B (zh) * | 2008-05-02 | 2017-06-11 | 艾西利羅製藥公司 | 調節血管新生與周圍細胞組成的方法與組合物 |
| CA2724525A1 (en) * | 2008-05-15 | 2009-11-19 | Acceleron Pharma, Inc. | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
| EP2809335A4 (en) * | 2012-02-02 | 2015-10-28 | Acceleron Pharma Inc | ALK1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF NIERENZELLENKARZINOMEN |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| CN105658672A (zh) * | 2013-08-22 | 2016-06-08 | 阿塞勒隆制药公司 | TGF-β受体II型变体及其用途 |
| JP2016036322A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | 血管新生因子と結合するキメラタンパク質 |
| BR112017021510A2 (pt) * | 2015-04-06 | 2018-07-03 | Acceleron Pharma Inc | heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização |
| JP6810702B2 (ja) * | 2015-04-06 | 2021-01-06 | アクセルロン ファーマ インコーポレイテッド | シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用 |
| CN110452295B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 抗肿瘤蛋白内皮抑素的衍生物 |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| WO2018067874A1 (en) | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Variant actriib proteins and uses thereof |
| WO2019086331A2 (en) * | 2017-11-02 | 2019-05-09 | Bayer Aktiengesellschaft | Bispecific antibodies binding alk-1 and bmpr-2 |
| CN114028541A (zh) * | 2021-05-21 | 2022-02-11 | 中山大学 | Gdf2在制备改善肿瘤异常血管的药物中的用途 |
| WO2024153115A1 (zh) * | 2023-01-18 | 2024-07-25 | 开拓药业(广东)有限公司 | 抗alk-1抗体及其用途 |
| AU2024252640A1 (en) | 2023-04-07 | 2025-10-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8529014D0 (en) | 1985-11-25 | 1986-01-02 | Biogen Nv | Enhanced secretion of heterologous proteins |
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| CA2147754A1 (en) | 1992-10-30 | 1994-05-11 | Michelle Letarte | Compositions and methods for modifying the regulatory activity of tgf- .beta. |
| US5830847A (en) | 1992-10-30 | 1998-11-03 | Hsc Research & Development Limited Partnership | Soluble TGF-β-binding endoglin polypeptides and homodimers |
| AU683431B2 (en) | 1992-11-17 | 1997-11-13 | Ludwig Institute For Cancer Research | Activin receptor-like kinases, proteins having serine/ threonine kinase domains and their use |
| US6692925B1 (en) | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
| US7592428B1 (en) | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| WO1997007135A2 (en) | 1995-08-14 | 1997-02-27 | Creative Biomolecules, Inc. | Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof |
| ES2169864T3 (es) | 1996-05-31 | 2002-07-16 | Health Research Inc | Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis. |
| US6190660B1 (en) | 1996-05-31 | 2001-02-20 | Health Research, Inc. | Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy |
| MX9701946A (es) | 1997-03-14 | 1998-04-30 | Arturo Jimenez Bayardo | Solucion oftalmica transportadora. |
| WO1998047531A2 (en) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| WO1999046386A1 (en) | 1998-03-13 | 1999-09-16 | Ludwig Institute For Cancer Research | ALK-1 RESPONDS TO TGF-β AND SIGNALS THROUGH SMAD-1 AND SMAD-5 |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US20030012792A1 (en) | 1998-05-22 | 2003-01-16 | Holaday John W. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| US6413513B1 (en) | 1998-05-22 | 2002-07-02 | Entremed, Inc. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| US7740841B1 (en) | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
| US7077836B2 (en) | 2000-07-21 | 2006-07-18 | Vein Rx, Inc. | Methods and apparatus for sclerosing the wall of a varicose vein |
| WO2002011785A2 (en) | 2000-08-03 | 2002-02-14 | The University Of Utah Research Foundation | Manipulation of arterial-venous identity |
| DE10043481A1 (de) | 2000-09-04 | 2002-04-11 | Vectron Therapeutics Ag Imt | Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung |
| CN1685055A (zh) | 2001-10-31 | 2005-10-19 | 爱尔康公司 | 骨形态发生蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途 |
| WO2003064628A2 (en) | 2002-02-01 | 2003-08-07 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
| US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| CA2484994C (en) | 2002-04-29 | 2016-06-14 | St. Louis University | Peptide antagonists of tgf-beta family members and therapeutic uses thereof |
| EP1534318A4 (en) | 2002-06-27 | 2009-07-01 | Univ Utah Res Found | METHOD AND COMPOSITIONS FOR MANIPULATING GUIDED NAVIGATION OF ENDOTHONE TUBES IN THE ANGIOGENESIS |
| WO2004039248A2 (en) | 2002-10-31 | 2004-05-13 | The General Hospital Corporation | Repairing or replacing tissues or organs |
| EP1646655A2 (en) | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 ligands |
| WO2005044849A2 (en) | 2003-08-05 | 2005-05-19 | Eli Lilly And Company | Lp mammalian proteins; related reagents |
| EP1721257A2 (en) | 2004-01-27 | 2006-11-15 | Compugen Ltd. | Differential expression of markers in ovarian cancer |
| US7101618B2 (en) * | 2004-05-07 | 2006-09-05 | 3M Innovative Properties Company | Article comprising fluorochemical surface layer |
| WO2005113590A2 (en) * | 2004-05-12 | 2005-12-01 | Acceleron Pharma Inc. | Bmp10 propeptides and related methods |
| US7897581B2 (en) | 2005-02-24 | 2011-03-01 | Massachusetts Eye & Ear Infirmary | Methods and compounds for promoting vessel regression |
| DK1933871T3 (da) * | 2005-09-07 | 2013-07-08 | Amgen Fremont Inc | Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 |
| US20090170767A1 (en) | 2006-05-31 | 2009-07-02 | Beth Israel Deaconess Medical Center | Soluble Endoglin Compounds for the Treatment and Prevention of Cancer |
| US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| WO2008057461A2 (en) | 2006-11-02 | 2008-05-15 | Acceleron Pharma, Inc. | Alk1 receptor and ligand antagonists and uses thereof |
| US10059756B2 (en) * | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
| KR20100090683A (ko) * | 2007-11-09 | 2010-08-16 | 제넨테크, 인크. | 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법 |
| TWI586364B (zh) * | 2008-05-02 | 2017-06-11 | 艾西利羅製藥公司 | 調節血管新生與周圍細胞組成的方法與組合物 |
| CA2724525A1 (en) * | 2008-05-15 | 2009-11-19 | Acceleron Pharma, Inc. | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
-
2009
- 2009-05-01 TW TW098114652A patent/TWI586364B/zh not_active IP Right Cessation
- 2009-05-01 KR KR1020177002063A patent/KR20170012595A/ko not_active Ceased
- 2009-05-01 KR KR1020107027046A patent/KR20110031908A/ko not_active Ceased
- 2009-05-01 MX MX2017011333A patent/MX391905B/es unknown
- 2009-05-01 CA CA2723449A patent/CA2723449C/en active Active
- 2009-05-01 AU AU2009241755A patent/AU2009241755B2/en not_active Ceased
- 2009-05-01 KR KR1020217003129A patent/KR20210014224A/ko not_active Withdrawn
- 2009-05-01 KR KR1020187006926A patent/KR20180029111A/ko not_active Ceased
- 2009-05-01 KR KR1020197032900A patent/KR20190128254A/ko not_active Withdrawn
- 2009-05-01 KR KR1020197008836A patent/KR20190037355A/ko not_active Withdrawn
- 2009-05-01 BR BRPI0911853A patent/BRPI0911853A8/pt not_active IP Right Cessation
- 2009-05-01 US US12/434,598 patent/US8158584B2/en active Active
- 2009-05-01 EP EP18154273.9A patent/EP3398966A1/en active Pending
- 2009-05-01 TW TW106106131A patent/TWI672151B/zh not_active IP Right Cessation
- 2009-05-01 KR KR1020207018412A patent/KR20200079567A/ko not_active Withdrawn
- 2009-05-01 KR KR1020217028926A patent/KR20210113446A/ko not_active Ceased
- 2009-05-01 CN CN200980125712.3A patent/CN102099374B/zh not_active Expired - Fee Related
- 2009-05-01 EP EP09739231A patent/EP2283040A2/en not_active Withdrawn
- 2009-05-01 CN CN201610297436.0A patent/CN105963695A/zh active Pending
- 2009-05-01 WO PCT/US2009/002699 patent/WO2009134428A2/en not_active Ceased
- 2009-05-01 JP JP2011507463A patent/JP5719766B2/ja not_active Expired - Fee Related
- 2009-05-01 TW TW104119480A patent/TW201609138A/zh unknown
- 2009-05-01 MX MX2010011998A patent/MX2010011998A/es active IP Right Grant
-
2012
- 2012-04-13 US US13/447,077 patent/US20130039910A1/en not_active Abandoned
-
2014
- 2014-11-25 JP JP2014237666A patent/JP6194302B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-04 AU AU2016200018A patent/AU2016200018A1/en not_active Abandoned
-
2017
- 2017-02-28 JP JP2017037131A patent/JP2017101068A/ja not_active Withdrawn
-
2018
- 2018-01-11 AU AU2018200237A patent/AU2018200237B2/en not_active Ceased
- 2018-02-13 US US15/895,894 patent/US20180179293A1/en not_active Abandoned
-
2019
- 2019-09-18 AU AU2019232838A patent/AU2019232838B2/en not_active Ceased
- 2019-09-20 JP JP2019171838A patent/JP2019210298A/ja not_active Withdrawn
-
2021
- 2021-01-04 US US17/140,398 patent/US20210388104A1/en not_active Abandoned
- 2021-09-03 JP JP2021144016A patent/JP2021183652A/ja active Pending
- 2021-12-13 AU AU2021286240A patent/AU2021286240A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017101068A5 (enExample) | ||
| US20240018257A1 (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| ES2752248T3 (es) | Heterodímero proteínico y uso del mismo | |
| ES2808153T3 (es) | Terapia de combinación para tratamiento de enfermedad | |
| JP6355032B2 (ja) | 新規組換え二機能性融合タンパク質、それらの調製および使用 | |
| US20170002060A1 (en) | Polynucleotides for the in vivo production of antibodies | |
| JP2011520793A5 (enExample) | ||
| WO2015105926A1 (en) | Polynucleotides for the in vivo production of antibodies | |
| JP6519090B2 (ja) | 血管内皮成長因子融合タンパク質 | |
| JP2016539096A5 (enExample) | ||
| BR112016002614B1 (pt) | Imunocitoquina e composição farmacêutica | |
| JP7048567B2 (ja) | 二重特異性抗原結合ポリペプチド | |
| JP2018506277A5 (enExample) | ||
| WO2016180034A1 (zh) | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 | |
| ES2966030T3 (es) | Anticuerpos anti-VEGFR-2/KDR humanos | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| JP2022511286A (ja) | Ｓｉｒｐアルファ系キメラタンパク質を含む併用療法 | |
| AU2011293554B9 (en) | Treatment for neoplastic diseases | |
| JP2018529661A5 (enExample) | ||
| US20230235073A1 (en) | Anti-cd36 antibodies and their use to treat cancer | |
| Markatseli et al. | Certolizumab for rheumatoid arthritis | |
| CN104774264A (zh) | 抗人proBDNF单克隆抗体及其在疼痛中的作用 | |
| JP2017513857A (ja) | Ｃｄ１４７に結合する抗体医薬 | |
| EP2125895A2 (en) | Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis | |
| CA3168923A1 (en) | Combination therapy for treatment of cancer and cancer metastasis |